Bio-Technology General's BioLon
This article was originally published in The Gray Sheet
U.S. marketing of the viscoelastic ophthalmic product, which is indicated as a surgical aid for cataract extraction, intraocular lens implantation and anterior segment surgery, begins Nov. 9. BTG's distributor, Akorn, enters agreements with Allergan and Allegiance to provide "over 200" sales reps to market the device, a premarket approval application for which was approved in July. BTG attributes the delay of the launch to the need to finalize labeling and ramp up production at its Rehovot, Israel, manufacturing facility
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.